Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of GNC-035 in relapsed or refractory CLL/SLL and other hematologic malignancies
CTR20232072Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GNC-035 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL) and hematopoietic malignancies, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose or maximum administered dose and 3 more. Started Sep 2023; status: active.
02
Drugs
GNC-035
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)hematopoietic malignancies
Beyond the preview
Go deeper on CTR20232072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232072.